Expert Ratings For Medtronic
Portfolio Pulse from Benzinga Insights
Recent analyst ratings for Medtronic (NYSE:MDT) show a mix of bullish and indifferent stances, with an updated average 12-month price target of $91.75, marking a 5.46% increase from the previous target. Analysts from Mizuho, Truist Securities, and RBC Capital have raised their price targets, reflecting optimism about Medtronic's market position and financial health. Despite this, Medtronic's financial indicators such as ROE and ROA are below industry standards, suggesting challenges in capital and asset utilization.
February 21, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analyst ratings for Medtronic have recently become more optimistic, with raised price targets suggesting a positive outlook on the company's future performance. However, financial metrics indicate underlying challenges in efficiency and profitability.
The increase in the average price target by analysts reflects a positive short-term outlook for Medtronic, potentially leading to an uptick in investor confidence and stock price. However, the concerns raised about ROE and ROA could temper long-term expectations, making the short-term impact more positive due to the recent analyst upgrades.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100